

## Ziprasidone Mesylate Syrup 2.5 mg/mL

### INGREDIENTS:

Ziprasidone mesylate 20 mg injection	8 vials
Distilled water	9.6 mL
Ora-Sweet	QSAD: 64 mL

### EQUIPMENT AND SUPPLIES:

Containment ventilated enclosure (CVE) or biological safety cabinet (BSC), 2 × 18-G needles, 1 × 3-mL syringe, 1 × 10-mL syringe, graduated cylinder

### PREPARATION DETAILS:

**Caution: Hazardous Drug—Reproductive hazards: Must be prepared in compliance with USP <800>.**

1. Reconstitute each vial of injectable powder with 1.2 mL of distilled water.
2. Withdraw the contents from each vial into a syringe.
3. Transfer the solution to a graduated cylinder.
4. Add vehicle to the graduated cylinder to achieve the total volume indicated above.
5. Transfer contents of the graduated cylinder into an appropriately sized amber bottle.
6. Shake well to mix.

**Quality-Control Procedures** — Visually inspect for physical appearance of formulation and container closure integrity (no leakage, cracks in container, or improper seals).

**Labeling Requirements** — Extemporaneously compounded preparation. Caution: reproductive hazards. For oral use only. Store at room temperature or refrigerate. Protect from light. Shake well before use.

**Storage Conditions/Stability** — Store at room temperature or refrigerate. Protect from light. Stable for 42 days when refrigerated and 14 days when stored at room temperature.

### STABILITY STUDY DETAILS:

**Study Container Type** — Brown plastic prescription bottle

**Referenced Manufacturers** — Ziprasidone mesylate injection (Geodon, Pfizer); Ora-Sweet (Paddock Laboratories, LLC); distilled water (not specified).

**Stability-Indicating Study** — No

### REFERENCE

1. Green K, Parish RC. Stability of ziprasidone mesylate in an extemporaneously compounded oral solution. *J Pediatr Pharmacol Ther.* 2010;15:138-141.